India, May 11 -- Biocon Ltd on Monday announced that its subsidiary, Biocon Pharma Ltd, has received approval from Health Canada for Micafungin for Injection used in the treatment of fungal infections.
According to the company's regulatory filing, the approval covers Micafungin for Injection in strengths of 50 mg and 100 mg.
The approved drug is indicated for use in adults and children aged four months and above for the treatment of candidemia, acute disseminated candidiasis, candida peritonitis, abscesses, and other serious fungal infections.
Published by HT Digital Content Services with permission from Dion Global Solutions Limited....